LabGenius

LabGenius is a drug discovery company utilizing machine learning to discover novel therapeutic antibodies. Its smart robotic platform, EVA, designs, conducts, and learns from experiments, rapidly identifying high-performing antibodies. This addresses the challenge of on-target, off-tumor toxicity in therapeutic antibody development.

Funding Round: Series B

Funding Amount: £35M

Date: 22-May-2024

Investors: M Ventures, Octopus Ventures, LG Corp, Atomico, Kindred Capital, Lux Capital, Obvious Ventures

Markets: Biotechnology, Pharmaceuticals, Machine Learning, AI, Therapeutics, Robotics

HQ: London, England, United Kingdom

Founded: 2012

Website: https://www.labgeniustx.com/

LinkedIn: https://www.linkedin.com/company/labgeniustx

Twitter: https://twitter.com/labgeni_us

Instagram:

Facebook: https://www.facebook.com/AIdrivenEvolution